Acurx Pharmaceuticals, Inc. (ACXP)
NASDAQ: ACXP · Real-Time Price · USD
0.9600
-0.0250 (-2.54%)
At close: Nov 13, 2026, 4:00 PM EST
1.010
+0.050 (5.21%)
After-hours: Nov 13, 2026, 7:29 PM EST
Company Description
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections in the United States.
The company’s lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections.
It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus (MRSA), vancomycin resistant enterococcus (VRE), and drug-resistant streptococcus pneumoniae (DRSP), as well as B.
anthracis. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.
Acurx Pharmaceuticals, Inc.
| Country | United States |
| Founded | 2017 |
| IPO Date | Jun 25, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 4 |
| CEO | David Luci |
Contact Details
Address: 259 Liberty Avenue Staten Island, New York 10305 United States | |
| Phone | 917 533 1469 |
| Website | acurxpharma.com |
Stock Details
| Ticker Symbol | ACXP |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $6.00 |
| CIK Code | 1736243 |
| CUSIP Number | 00510M203 |
| ISIN Number | US00510M2035 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| David P. Luci CPA, Esq., J.D. | Co-Founder, President, Chief Executive Officer, Corporate Secretary and Director |
| Robert J. DeLuccia | Co-Founder and Executive Chairman |
| Robert G. Shawah CPA | Co-Founder and Chief Financial Officer |
| Dr. Michael H. Silverman B.Sc., F.A.C.P., FACR, M.B.A., M.D. | Medical Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 13, 2026 | 8-K | Current Report |
| Nov 12, 2026 | 10-Q | Quarterly Report |
| Oct 29, 2026 | 8-K | Current Report |
| Oct 16, 2026 | 8-K | Current Report |
| Sep 17, 2026 | EFFECT | Notice of Effectiveness |
| Sep 17, 2026 | 424B3 | Prospectus |
| Sep 8, 2026 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Sep 1, 2026 | ARS | Filing |
| Sep 1, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Sep 1, 2026 | DEF 14A | Other definitive proxy statements |